Searchable abstracts of presentations at key conferences in endocrinology

ea0019p241 | Pituitary | SFEBES2009

The acromegalic cardiovascular and respiratory outcomes with primary analogue therapy (A.C.R.O.P.A.T.) trial

Webb A , Gayton E , Annamalai A , Pilsworth S , Wallace S , Khan S , O'Toole S , Ariyaratnam S , Maki-Petaja K , Scoffings D , Antoun N , Wilkinson I , Dutka D , Shneerson J , Simpson H , Gurnell M

Seventeen newly-diagnosed acromegalic patients (8 female, 9 male: mean age 55 year, range 26–73 year) were recruited to the A.C.R.O.P.A.T. trial. Patients were assessed prior to, and following, 6 months of treatment with Somatuline Autogel® (SA).Growth hormone (GH) & insulin-like growth factor 1 (IGF1): Following treatment, GH and IGF1 levels fell significantly in all but one subject: median GH change −17.23 mU/l (interquar...